





- The fertilizer producer Neochim (**3NB**) reported loss during the seasonally strong first quarter. Although the negative result is less than the previous two quarters, the company's profit is highly dependent on the first three months of the year. Moreover, Neochim will report deep loss for the year.
- The company did not reported the reasons for its weak performance during the quarter. Domestic sales fell by 20%, while export revenues dropped by 43% due to the lost markets in Asia and Africa. Sales to European countries were 15% lower. This could be related to the drop of prices of ammonia fertilizers.
- The production costs fell less than the decrease of revenues and were the main reason behind the quarterly loss. However, prices of fertilizers are expected to rise due to better demand in April after

the long period of decline that the sector is experiencing for the last 18 months. The market of fertilizers is rising steadily and consumers are switching toward more complex products.

- The situation in Ukraine is crucial for the market of fertilizers in the region. Cheap production from Ukraine will cease to be factor for price pressure as Russia stop to sell cheap natural gas for the country. Moreover, the inefficient production of Ukraine will also result to sizable decrease of supply that will create better market conditions for Neochim to export in the region.
- At the end of the last year, the European leader in production and trade with fertilizers Borealis bought 20% of shares of Neochim. We consider the entry as major step toward the increase of revenues and profits of Neochim.

	1Q 2014	q-o-q	y-o-y
Revenues	81 624	46.40%	-28.30%
Costs, incl. depreciation	82 704	29.50%	-18.83%
Interest expenses	2 647	-2.83%	4.29%
EBITDA	505	-11.56%	44.29%
EBIT	1 569	-125.22%	-89.24%
Net profit	-1 078	-87.95%	-109.0%
Assets	-1 583	-83.36%	-
Long-term assets	163 490	-2.85%	-1.11%
Inventories	109 357	-1.04%	2.36%
Receivables	24 785	-12.74%	-11.19%
Cash	23 157	-2.24%	22.73%
Equity	628	15.65%	-78.54%
Long-term loans	94 845	-1.10%	-17.24%
Short-term loans	18 049	5.88%	1.2%
	17 043	15.30%	



*Source: Neochim; '000 BGN

VALUATION

The table presents the main valuation multiples of Neochim, calculated with the unconsolidated results for each year.

Multiples comparison

	2012	2013	12M
Last Price	28.30	53.00	52.90
Number of Shares	2 585 876	2 585 876	2 654 358
Market Capitalization	73 180 278	137 051 405	140 415 538
Net Profit	-9 434 000	-9 516 000	-18 775 000
P/E	-7.76	-14.40	-7.48
Equity	102 280 000	95 901 000	94 845 000
P/B	0.72	1.43	1.48
Sales	253 055 000	248 598 000	216 397 000
P/S	0.29	0.55	0.65
EV	90 758 494	104 465 278	171 515 405
EBITDA	1 564 000	6 973 000	-6 040 000
EV/EBITDA	58.03	14.98	-28.40
RoE	-9.22%	-9.92%	-19.80%
RoA	-5.41%	-5.65%	-11.48%

The difficult market conjuncture had negative impact on valuation ratios of Neochim for consecutive year. Moreover, the first quarter is predicting very negative result for 2014 unless the cooperation with Borealis did not provide sudden increase of revenues from foreign markets or the company takes the place of Ukrainian producers on the domestic market. This is not impossible, although in short-term we see the possibility of cheap import from Ukraine due to the devaluation of the currency and the fact that Ukraine is not paying for natural gas.

Comparison to industry

Mutiples	P/E	P/B	P/S	EV/EBITDA
Median	13.00	1.23	0.69	7.20
Market Capitalization	-244 075 000	117 078 043	149 920 058	-77 967 662
Price	-91.95	44.11	56.48	-29.37
Weight	0%	50%	50%	0%
Current Price		52.90		
Fair Price		50.29		
Premium (Discount) to Current Price		-4.93%		

The loss is making Neochim incomparable to peers

Profit related multiples are negative and make Neochim incomparable to peers. We present the table with calculations for informational purposes and not for valuation purposes. The stock is in line with the valuation of peers by comparing to book value and revenues.

Forecasts – conservative scenario

Statement of income (000 BGN)	2011	2012	2013P	2014E	2015E	2016E	2017E	2018E
Net Sales	284 309	253 055	248 598	218 766	290 959	363 699	429 165	493 539
Material costs	222 767	209 306	195 479	185 951	226 948	276 411	317 582	365 219
Sales and administrative costs	36 218	40 904	39 057	32 815	43 644	49 099	57 937	65 394
EBITDA	32 719	1 564	6 973	3 281	14 548	20 003	25 750	29 612
Depreciation and amortization	9 510	9 957	10 376	8 751	11 638	14 548	16 094	18 508
EBIT	23 209	-8 393	-3 403	-5 469	2 910	5 455	9 656	11 105
Interest expenses	1 041	1 041	2 095	2 305	2 535	1 901	1 426	1 782
Net profit	19 644	-9 434	-5 498	-7 774	337	3 199	7 407	8 390

The company will turn into profit in 2015

The weak start of the year is the reason to decrease or expectations for revenues in 2014. However, we consider this year as exceptional – media reports are suggesting that fertilizer prices are recovering and that domestic market will turn to growth. In light of the recent events in Ukraine we are becoming more positive on Neochim in long-term. This is why we expect gradual improvement of EBITDA margin from 5% in 2015 to 7% in 2021. Moreover, the company's productivity will improve due to recent investments. Interest expenses will decrease as investments are concentrated more in the next few years. Net profit will be positive next year. We consider this as conservative scenario as history showed that the company can achieve even higher increase of revenues if demand is present.

Discounted cash flows

Neochim											Terminal
BGN'000	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Year
EBIT	-5 469	2 910	5 455	9 656	11 105	14 930	16 124	20 199	21 209	22 057	22 829
EBIT(1-T)	-4 922	2 619	4 910	8 691	9 994	13 437	14 512	18 179	19 088	19 851	20 546
Add: D&A	8 751	11 638	14 548	16 094	18 508	20 358	21 987	23 306	24 472	25 451	26 341
Less: Investments	12 032	14 548	18 185	12 875	14 806	10 858	11 726	21 753	22 840	23 754	26 341
Less: Change NWC	1 091	722	2 546	982	966	3 455	869	704	622	522	475
FCF	-9 294	-1 013	-1 273	10 927	12 730	19 482	23 904	19 029	20 098	21 026	20 071
PV FCF	-8 449	-837	-956	7 464	7 904	10 997	12 266	8 877	8 523	8 106	
Sum of PV FCF	53 896										
PV of Continuing Value	119 051										
Total PV Free Cash Flows	172 947										
Less: Outstanding Debt	35 092										
Plus: Financial Assets	628										
PV of Equity	138 483										
Number of Shares	2 654										
Price Per share	52.17										
			WACC								
				Growth Rate							
				SA	2.0%	3.0%	3.5%	4.0%	5.0%		
				8.0%	68.94	80.62	88.40	98.13	127.32		
				9.0%	54.51	62.11	66.95	72.76	88.73		
				10.0%	43.76	48.97	52.17	55.91	65.63		
				11.0%	35.47	39.17	41.39	43.93	50.27		
				12.0%	28.90	31.60	33.19	34.98	39.33		

RECOMMENDATION AND PRICE TARGET

Recommendation:
HOLD
Target Price: **52.00**
BGN
Increase: **0%**

Discounting our expectations for the company's development for the next ten years resulted to price per share that corresponds to the latest quotes. Although higher risk premium than 10% is not justifying the current price, we are confident that Neochim will manage to show good results after the strategic alliance with Borealis. What we lack now is the proof of it and the effects from the crisis in Ukraine. Nevertheless, the market is giving good credit of confidence to the stock and we don't see high risks of price decrease in the next two quarters.

Financial Data

Statement of Income (in '000 BGN)	2009	2010	2011	2012	2013
Sales	104 084	159 618	284 300	253 055	248 620
Production expenses	97 133	144 981	229 764	229 291	216 732
Personnel expenses	17 133	16 196	23 104	22 194	24 272
Net income from financial activities	280	1 403	1 287	(6)	(663)
Other revenues and expenses	0	0	0	0	0
EBITDA	(9 902)	(156)	32 719	1 564	6 953
Depreciation	8 829	8 961	9 510	9 957	10 366
EBIT	(18 731)	(9 117)	23 209	(8 393)	(3 413)
Interest expense	1 058	1 725	1 041	1 041	2 095
Pretax income	(19 789)	(10 842)	22 168	(9 434)	(5 508)
Taxes	(1 940)	(1 062)	0	0	(537)
After-tax income	(17 849)	(9 780)	22 168	(9 434)	(4 971)
Minority interest	0	0	0	0	0
Net income	(17 849)	(9 780)	22 168	(9 434)	(4 971)
Earnings per share in BGN	(6.72)	(3.68)	8.35	(3.55)	(1.87)

Balance Sheet (in '000 BGN)	2009	2010	2011	2012	2013
Total Assets	156 549	143 699	164 070	174 361	168 927
Equity subscriptions receivable	0	0	0	0	0
Fixed assets	107 388	104 143	104 744	115 573	115 866
Tangible fixed assets	98 694	93 910	94 134	106 549	110 628
Financial investments	4 159	4 159	4 159	4 242	4 242
Current assets	49 161	39 556	59 326	58 788	53 061
Inventory	33 817	23 398	32 798	33 811	28 360
Receivables	14 155	13 320	23 067	18 674	23 717
Financial assets	0	0	0	0	0
Cash and cash equivalents	745	2 362	3 053	5 906	543
Total liabilities + equity	156 549	143 699	164 070	174 361	168 927
Equity	102 647	92 867	115 035	102 280	96 428
Registered capital	2 586	2 586	2 586	2 586	2 586
Capital funds	(3 242)	(3 242)	(3 242)	(3 242)	(4 042)
Earnings	103 303	93 523	115 691	102 936	97 884
Liabilities	53 902	50 832	49 035	72 081	72 499
Long-term payables	14 569	8 476	5 246	22 512	3 488
Long-term bank loans	6 221	2 472	1 225	16 895	17 047
Short-term bank debt	20 276	8 489	14 772	13 384	14 781
Short-term payables	(6 024)	33 867	29 017	36 185	37 183
Other liabilities	0	0	0	0	0
Working capital	34 909	(2 800)	15 537	9 219	1 097

Cash Flow Statement (in '000 BGN)	2009	2010	2011	2012	2013
Net income	(17 849)	(9 780)	22 168	(9 434)	(4 971)
Depreciation	8 829	8 961	9 510	9 957	10 366
Changes in Working capital	(23 040)	(37 709)	18 337	(6 318)	(8 122)
Other operating cash flow items	9 145	65 083	(45 376)	16 979	10 409
Net cash from operating activities	(22 915)	26 555	4 639	11 184	7 682
Capital expenditures	(4 615)	(3 714)	(8 096)	(22 106)	(13 198)
Other investing cash flow items	0	0	97	0	0
Net cash from investing activities	(4 615)	(3 714)	(7 999)	(20 236)	(13 169)
Issuance/ Retirement of Stock, Net	0	0	0	0	0
Issuance/ Retirement of Debt, Net	21 689	(20 410)	4 186	12 462	2 443
Dividends paid	(31)	(1)	(4)	(333)	(1 026)
Other financing cash flow items	(764)	(813)	(131)	(224)	(1 293)
Net cash from financing activities	20 894	(21 224)	4 051	11 905	124
Net change in cash	(6 636)	1 617	691	2 853	(5 363)
Beginning-of-period cash	7 381	745	2 362	3 053	5 906
End-of-period cash	745	2 362	3 053	5 906	543
Cash per share	0.28	0.89	1.15	2.23	0.20

Financial and Performance Indicators	2009	2010	2011	2012	2013
Valuation Ratios					
Price/Earnings (P/E)	-3.72	-7.98	3.60	-7.96	-28.30
Book Value (BV)	38.67	34.99	43.34	38.53	36.33
Price/Book (P/B)	0.65	0.84	0.69	0.73	1.46
Sales Per Share	39.21	60.13	107.11	95.34	93.66
Price/Sales (P/S)	0.64	0.49	0.28	0.30	0.57
Price/Cash per share	-7.36	-95.28	2.52	143.63	26.08
EV (in BGN)	92 137	86 637	92 707	99 491	171 966
EV/Sales	0.89	0.54	0.33	0.39	0.69
EV/EBITDA	-9.30	-555.37	2.83	63.61	24.73
EV/EBIT	-4.92	-9.50	3.99	-11.85	-50.39
Liquidity					
Current ratio	3.45	0.93	1.35	1.19	1.02
Quick ratio	1.08	0.38	0.61	0.50	0.48
Debt Management					
Debt to total assets	0.34	0.35	0.30	0.41	0.43
Interest coverage	-17.70	-5.29	22.29	-8.06	-1.63
LT Debt/Equity	0.20	0.12	0.06	0.39	0.21
Total Debt/Equity	0.53	0.55	0.43	0.70	0.75
Asset Management					
Inventory turnover	3.08	6.82	8.67	7.48	8.77
Days sales outstanding	49	30	29	27	34
Fixed asset turnover	0.97	1.53	2.71	2.19	2.15
Total asset turnover	0.66	1.11	1.73	1.45	1.47
Profitability					
Profit margin on sales	-17.1%	-6.1%	7.8%	-3.7%	-2.0%
EBITDA margin	-9.5%	-0.1%	11.5%	0.6%	2.8%
Basic earning power	-12.0%	-6.3%	14.1%	-4.8%	-2.0%
Return on assets	-11.4%	-6.8%	13.5%	-5.4%	-2.9%
Return on equity	-17.4%	-10.5%	19.3%	-9.2%	-5.2%
Return on investments	-14.5%	-9.4%	18.2%	-6.7%	-4.3%
Dividend Information					
Dividend Yield	-	-	1.00%	1.41%	-
Dividend per share	-	-	0.30	0.40	-
Number of shares:					
	2 654 358	2 654 358	2 654 358	2 654 358	2 654 358
Price in BGN - period end:					
	25.01	29.40	30.05	28.30	53.00
Market cap in BGN - period end:					
	66 385 494	78 038 125	79 763 458	75 118 331	140 680 974

Disclaimer

Regulatory Restrictions: No publication of ELANA Trading should be construed as an offer (or solicitation of an offer) to **U.S. persons** to buy or sell financial instruments or any financial product, make any investment or participate in any particular trading strategy (collectively "Offers"). No Publication of ELANA Trading should be construed as an Offer (or solicitation of an offer) in any jurisdiction in which such Offer would be illegal. Any such perceived Offer will not be honoured by ELANA Trading.

Analyst Certification: The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document.

Financial Interest: ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted.

Regulatory Authority: Financial Supervisory Commission, *Shar Planina* Street 33, 1303 Sofia, Bulgaria

Information Disclosure: All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading's calculations.

Risks for Investors: Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety.

The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments.

Valuation Methods: Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation.

Recommendations: Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

BUY	More than 5% higher as compared to SOFIX and BG40 performance
HOLD	Market performance, +/-5% as compared to SOFIX and BG40
SELL	More than 5% lower as compared to SOFIX and BG40 performance

Frequency of Recommendations: No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes.

Copyrights: The copyrights of ELANA Trading analyses belong to the Research Department of the brokerage and their content cannot be used for commercial purposes. Replication and redistribution of ELANA Trading analyses content is expressly prohibited without the prior written consent of the appointed contacts listed below.

For more information, please contact:

Research analyst
Tsvetoslav Tsachev

Phone:
+359 2 810 00 23

E-mail:
tsachev@elana.net

Internet:
www.elana.net